| Business Summary | | Oncor
Inc.
sold
its
80%
interest
in
Appligene
Oncore,
a
French
company,
to
a
Canadian
company
for
$1
million
in
February
1999.
After
the
sale
of
Appligene,
the
Company's
only
remaining
assets
consisted
of
certain
Oncor
and
Codon
intellectual
property
and
licenses.
The
future
uses,
if
the
Company
is
exploring
any,
of
these
remaining
assets.
In
February
1999,
Oncor,
Inc.
and
its
wholly-owned
subsidiary,
Codon
Pharmaceuticals,
Inc.,
filed
voluntary
petitions
for
relief
under
Chapter
11
of
the
United
States
Code
with
the
United
States
Bankruptcy
Court
for
the
District
of
Delaware,
Wilmington,
Delaware.
Oncor
expects
to
reorganize
under
Chapter
11
and
to
propose
a
reorganization
plan
or
plans. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Oncor
develops,
produces
and
markets
cancer-oriented
genetic
probes,
related
reagents,
molecular
biology
products
and
diagnostic
products
for
the
detection
and
management
of
certain
cancers.
For
the
six
months
ended
6/30/99,
revenues
fell
90%
to
$720
thousand.
Net
loss
applicable
to
Common
fell
93%
to
$1.1
million.
Revenues
reflect
the
company's
disposition
of
Appilgene.
Lower
loss
reflect
lowered
direct
costs
and
expenses
due
to
the
reduced
scope
of
operations. | More
from
Market Guide: Significant
Developments |
| Officers | | | FY1998 Pay | |
| Jose Coronas, 54 Chairman
and Acting Sec. | $133K | Dollar amounts are as of 31-Dec-1998 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|